Passing of Genmab A/S' Annual General Meeting

Core Points - Genmab A/S held its Annual General Meeting on March 12, 2025, where the Annual Report for 2024 was approved and the Board of Directors received discharge [2][5] - The company's profit for the year was DKK 7,844 million, which will be carried forward to retained earnings [3][5] - Six members of the Board of Directors were re-elected for a one-year term, and Deloitte was re-elected as the company's auditor [3][5][6] Financial Decisions - The 2024 Compensation Report was approved [3][5] - Proposals from the Board of Directors included amendments to the Remuneration Policy, remuneration for 2025, reduction of share capital by DKK 2,076,853 through cancellation of treasury shares, authorization to acquire treasury shares, and issuance of warrants [5][6] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives [4][7] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab aims to transform the lives of patients with cancer and other serious diseases by 2030 [4][7]